A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

[1]  L. Annemans,et al.  Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium , 2008, Supportive Care in Cancer.

[2]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Rousseau,et al.  On the Receiving End , 2006 .

[4]  Keunchil Park,et al.  Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Gralla,et al.  Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Edwards,et al.  Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. , 2004, Pharmacogenomics.

[7]  P. Lu,et al.  CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT , 2004, Drug Metabolism and Disposition.

[8]  G. de Pouvourville,et al.  Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics , 2004, Cancer.

[9]  H. Eichler,et al.  The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. de Wit,et al.  Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Pearson,et al.  Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall , 2003, Supportive Care in Cancer.

[13]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[14]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[15]  D. Osoba,et al.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Verweij,et al.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.

[17]  P. Butow,et al.  On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.